Research programme: targeted therapeutics - TiGenix
Alternative Names: Cyclodextrin polysulfate - TiGenix NV; Cyclodextrin polysulphate - TiGenix NVLatest Information Update: 03 Aug 2018
At a glance
- Originator TiGenix
- Class Carbohydrates; Cyclodextrins; Peptides; Sulfates
- Mechanism of Action Cartilage replacements; Interleukin 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cartilage disorders; Osteoarthritis
Most Recent Events
- 31 Jul 2018 TiGenix has been acquired by Takeda
- 31 Aug 2010 Discontinued - Preclinical for Cartilage disorders in Belgium (unspecified route)
- 31 Aug 2010 Discontinued - Preclinical for Osteoarthritis in Belgium (unspecified route)